Invitrogen and Emiliem Sign Major Kinase Screening Agreement
2007-03-29 08:00 (New York)
Kinase Drug Discovery Program Will Utilize Invitrogen's
SelectScreen(TM) Platform
CARLSBAD, Calif. & EMERYVILLE, Calif.--(BUSINESS WIRE)--March 29, 2007
Invitrogen Corporation (Nasdaq:IVGN), a provider of essential life
science technologies for disease research and drug discovery, today
announced a partnership with Emiliem, Inc. to screen the company's
multi-kinase inhibitors using Invitrogen's SelectScreen(TM) platform.
Invitrogen will perform biochemical kinase screening, cellular pathway
profiling and P450 screening of Emiliem's compounds targeting cancer.
Financial details of the multi-year agreement were not disclosed.
"We are fortunate to have a partner with the highest technical and
scientific standards in the industry and unmatched cellular screening
assays," said Dale E. Johnson, Pharm.D., Ph.D., President and CEO of
Emiliem. "We view Invitrogen as a key component of our research arm in
our quest to bring innovative therapeutics to cancer patients."
Invitrogen's SelectScreen(TM) profiling and screening service
integrates industry-leading enzyme collections and cell-lines with
state-of-the-art bioassay technologies to accelerate drug discovery
programs. The first phase of the agreement will use the
SelectScreen(TM) kinase profiling system to confirm specificity and
potency of compounds in the Emiliem pipeline created through its
K-STAR technology - a proprietary drug design platform for creating
compounds that inhibit multiple kinases and other cellular targets
known to be important in cancer progression. The second phase will use
Invitrogen's SelectScreen(TM) cell-based pathway profiling service to
interrogate the effects of Emiliem's compounds on biological pathways
and the company's cytochrome P450 profiling service to determine the
inhibitory profiles of lead molecules against drug metabolizing liver
enzymes.
"Our services will provide critical information to Emiliem,
including confirmation that Emiliem's compounds act on the kinases
they are targeted to, determination of the compounds' effects on
specific biological pathways and prediction of potential toxicity,"
noted Nick Ecos, Vice President and General Manager of Invitrogen's
Discovery Sciences business. "Our selection for this research
partnership demonstrates our strong credentials in kinase biology and
small molecule screening."
About Emiliem
Emiliem, Inc. is a developmental-stage biotechnology company
focused on the discovery and development of molecularly targeted
oncology drugs. The company has developed proprietary drug design
technologies that facilitate the inclusion of multiple kinase
inhibitor profiles into single compounds. Emiliem's approach to
developing targeted drugs includes the ability to identify proprietary
biomarkers. Coupling drug discovery with biomarker identification and
implementation increases the likelihood of achieving clinical trial
endpoints and receiving approval to market these innovative drug
candidates. The company is headquartered in Emeryville, California.
For more information, visit www.emiliem.com.
About Invitrogen
Invitrogen Corporation (Nasdaq:IVGN) provides products and
services that support academic and government research institutions
and pharmaceutical and biotech companies worldwide in their efforts to
improve the human condition. The company provides essential life
science technologies for disease research, drug discovery, and
commercial bioproduction. Invitrogen's own research and development
efforts are focused on breakthrough innovation in all major areas of
biological discovery including functional genomics, proteomics,
bioinformatics and cell biology -- placing Invitrogen's products in
nearly every major laboratory in the world. Founded in 1987,
Invitrogen is headquartered in Carlsbad, California, and conducts
business in more than 70 countries around the world. The company is
celebrating 20 years of accelerating scientific discovery. Invitrogen
globally employs approximately 5,000 scientists and other
professionals and had revenues of more than $1.26 billion in 2006. For
more information, visit www.invitrogen.com. |
